NASDAQ$AMED
Amedisys Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for Q3 2022 and updated 2022 guidance.
Amedisys reported a net service revenue increase of $4.5 million to $558.0 million compared to $553.5 million in 2021. Net income attributable to Amedisys, Inc. was $25.6 million compared to $45.0 million in 2021, with adjusted diluted earnings per share of $1.15 compared to $1.53 in 2021.
- Signed an innovative case rate arrangement with CVS/Aetna.
- Signed a comprehensive care at home partnership with The University of Arkansas for Medical Science.
- Enhancing benefit packages in 2023 and working on flexible scheduling to increase clinical capacity.
- Focusing on centralization and automation to remove the administrative load for caregivers and care center leadership.
Headline financials
Revenue & EPS history
Amedisys · Revenue · Quarterly
$558M
Forward guidance
Amedisys updated its 2022 guidance, anticipating adjusted net service revenue in the range of $2.224 billion to $2.230 billion, adjusted EBITDA in the range of $253 million to $258 million, and adjusted diluted earnings per share in the range of $4.82 to $4.93 based on an estimated 32.7 million shares outstanding.
Tailwinds
- Adjusted net service revenue is anticipated to be in the range of $2.224 billion to $2.230 billion.
- Adjusted EBITDA is anticipated to be in the range of $253 million to $258 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $4.82 to $4.93.
- Guidance is based on the current operating environment.
- The company is working on flexible scheduling and focusing on centralization and automation.
Headwinds
- COVID-19 continues to evolve in its disruptions to the healthcare systems and the economy.
- Any future regulations or government interventions could impact the ability to achieve this guidance.
- Extension of the public health emergency could impact the ability to achieve this guidance.
- Spike in clinicians and business development staff on quarantine could impact the ability to achieve this guidance.
- Staffing shortages could impact the ability to achieve this guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2022
-0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
46%
32 / 70 earnings
Positive
+25.6%
Q2 2014
Best reaction
-25.3%
Q3 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.2% | +1.0% | — | |
| Q1 2025 | +0.2% | -0.8% | -1.6% | |
| Q4 2024 | +0.1% | +0.6% | +1.5% | |
| Q3 2024 | +0.9% | -3.4% | -10.4% | |
| Q2 2024 | +0.0% | +0.5% | -0.2% | |
| Q1 2024 | +0.0% | +0.8% | +5.5% | |
| Q4 2023 | +0.9% | +0.6% | -1.6% | |
| Q3 2023 | -0.8% | -1.1% | +1.8% | |
| Q2 2023 | -0.6% | -0.2% | +2.5% | |
| Q1 2023 | +4.2% | +3.9% | +2.8% | |
| Q4 2022 | +5.4% | +2.2% | -23.6% | |
| Q3 2022 | -9.0% | -4.2% | -10.7% | |
| Q2 2022 | -3.8% | +0.9% | -4.5% | |
| Q1 2022 | +0.4% | -3.3% | -10.5% | |
| Q4 2021 | +5.8% | +14.5% | +18.4% | |
| Q3 2021 | +0.1% | +1.7% | -20.2% | |
| Q2 2021 | -22.8% | -22.9% | -29.3% | |
| Q1 2021 | +0.2% | — | — | |
| Q4 2020 | -6.2% | — | — | |
| Q3 2020 | -1.9% | — | — | |
| Q2 2020 | +3.7% | — | — | |
| Q1 2020 | -3.3% | — | — | |
| Q4 2019 | -2.1% | — | — | |
| Q3 2019 | -1.5% | — | — | |
| Q2 2019 | -1.9% | — | — | |
| Q1 2019 | -6.3% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | +17.3% | — | — | |
| Q2 2018 | +11.1% | — | — | |
| Q1 2018 | +7.2% | — | — | |
| Q4 2017 | +2.3% | — | — | |
| Q3 2017 | +4.8% | — | — | |
| Q2 2017 | -20.9% | — | — | |
| Q1 2017 | +4.4% | — | — | |
| Q4 2016 | +4.7% | — | — | |
| Q3 2016 | -10.1% | — | — | |
| Q2 2016 | -7.1% | — | — | |
| Q1 2016 | -7.0% | — | — | |
| Q4 2015 | +12.3% | — | — | |
| Q3 2015 | +10.8% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | +16.2% | — | — | |
| Q2 2014 | +25.6% | — | — | |
| Q1 2014 | -1.0% | — | — | |
| Q4 2013 | -10.0% | — | — | |
| Q3 2013 | -25.3% | — | — | |
| Q2 2013 | +17.8% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | -8.7% | — | — | |
| Q3 2012 | -5.0% | — | — | |
| Q2 2012 | +12.5% | — | — | |
| Q1 2012 | -1.2% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | -23.8% | — | — | |
| Q2 2011 | -10.7% | — | — | |
| Q1 2011 | -6.4% | — | — | |
| Q4 2010 | -8.0% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q2 2010 | -7.9% | — | — | |
| Q1 2009 | -4.3% | — | — | |
| Q1 2010 | +2.6% | — | — | |
| Q4 2007 | -1.3% | — | — | |
| Q4 2009 | -1.3% | — | — | |
| Q3 2008 | -5.7% | — | — | |
| Q3 2009 | -5.7% | — | — | |
| Q4 2008 | +7.6% | — | — | |
| Q2 2008 | +7.6% | — | — | |
| Q2 2009 | +7.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro